4 Largecap Export Stocks to Watch for Future Multibagger Potential: TCS, Sun Pharma, Torrent Pharma and Tech Mahindra
- October 26, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
TCS Rs 2,530. Sun Pharma Rs 1,748. Torrent Pharma Rs 4,524.40. Tech Mahindra Rs 1,790. Market caps from Rs 1.59 lakh crore to Rs 8.41 lakh crore. Data as of 23 Oct 2026.
Quick Answer
TCS, Sun Pharma, Torrent Pharma and Tech Mahindra are the 4 picks in this export stocks watchlist, with market caps between Rs 1.59 lakh crore and Rs 8.41 lakh crore. TCS stands out for the highest return on equity at 43.37%, while Sun Pharma offers the fastest profit growth, 35.75% a year since FY22. PE ratios run from 16.21 to 79.66, so compare each one with its industry PE before investing. All figures are as of 23 October 2026.
Export stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. TCS, Sun Pharma, Torrent Pharma and Tech Mahindra meet that test, with market caps from Rs 1.59 lakh crore to Rs 8.41 lakh crore and TCS offering the highest return on equity at 43.37%. Each of these companies has a return on equity of at least 10 per cent and net profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with a return on equity of at least 10 per cent and net profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening export stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 23 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Export Stocks and Why Do They Attract Multibagger Interest?
Export stocks are shares of large companies that earn a large part of their revenue from customers outside India, which gives them dollar income and exposure to global demand. The four here cover IT services, pharmaceuticals and telecom technology.
Companies that sell abroad spread their risk beyond one economy and often earn higher margins when the rupee is weak. For export stocks, both FY26 and the latest quarter showed growth. Investors researching export stocks get a fuller picture by reading growth and valuation together. The table below lines up export stocks on size, growth and valuation, using complete FY26 and latest quarter numbers. Past performance does not guarantee future returns, so use export stocks as a starting point for your own research.
Export Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 23 October 2026. TCS combines the lowest PE of the group, 16.21, with the highest return on equity, 43.37%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Tata Consultancy Services | 2,530 | 8,40,559 | 16.21 | 18.27 | 43.37% | 0.10 | 1,976.80 to 3,350.00 |
| Sun Pharmaceutical Industries | 1,748 | 4,20,024 | 34.66 | 36.42 | 13.74% | 0.06 | 1,583.70 to 2,046.90 |
| Torrent Pharmaceuticals | 4,524.40 | 1,71,745 | 79.66 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Tech Mahindra | 1,790 | 1,59,452 | 30.88 | 18.49 | 16.24% | 0.07 | 1,304.10 to 1,854.00 |
TCS: Return on Equity of 43.37%
TCS is India’s largest IT services company by market capitalisation and runs large AI and data practices for global clients. It reported FY26 revenue of Rs 2,71,423 crore, up 4.68% year on year, and net profit of Rs 49,454 crore, up 1.35%. Net profit has compounded at 6.49% a year since FY22, while revenue has grown 8.51% a year. Operating margin was 27.07% in FY26. The debt-to-equity ratio is 0.10, which keeps interest costs low.
In the September 2026 quarter, revenue rose 11.79% to Rs 74,525 crore and net profit grew 14.86% to Rs 13,934 crore. Domestic institutions raised their holding from 12.01% in June 2025 to 13.47% in June 2026. The stock trades at a PE of 16.21 against an industry PE of 18.27, below the sector average, with a return on equity of 43.37%. The dividend yield is 4.74%.
Sun Pharma: 35.75% Profit CAGR Since FY22
Sun Pharmaceutical Industries is one of India’s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
The stock trades at a PE of 34.66 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%. In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 79.66 against an industry PE of 36.42, with a return on equity of 25.49%.
Tech Mahindra: Debt-to-Equity of 0.07
Tech Mahindra, part of the Mahindra Group, provides IT and business services to telecom and other global clients. It reported FY26 revenue of Rs 56,847.30 crore, up 5.58% year on year, and net profit of Rs 4,805.50 crore, up 12.99%. Revenue has compounded at 5.57% a year since FY22. Operating margin was 15.47% in FY26. The debt-to-equity ratio is 0.07, which keeps interest costs low.
The stock trades at a PE of 30.88 against an industry PE of 18.49, with a return on equity of 16.24%. The dividend yield is 3.13%. In the September 2026 quarter, revenue rose 15.23% to Rs 16,172.80 crore and net profit grew 33.95% to Rs 1,609.70 crore. The share price is up 16.96% over the past year. Domestic institutions raised their holding from 32.13% in June 2025 to 36.92% in June 2026.
Export Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these export stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| TCS | 2,71,423 | 49,454 | 4.68% | 8.51% | 11.79% | 27.53% |
| Sun Pharma | 61,673.94 | 11,564.52 | 12.69% | 11.62% | 11.93% | 32.52% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 56.29% | 33.73% |
| Tech Mahindra | 56,847.30 | 4,805.50 | 5.58% | 5.57% | 15.23% | 17.74% |
Check the Univest Screener for live data on these export stocks
Institutional Holding in TCS, Sun Pharma, Torrent Pharma and Tech Mahindra
Institutional holding shows who is backing these export stocks alongside the promoter. The table uses the latest reported quarter for each. Tech Mahindra has the deepest institutional backing, with FII and DII together holding 55.58% as of June 2026. Domestic institutions increased their holding over the past year in TCS (from 12.01% to 13.47%), Sun Pharma (from 20.23% to 22.27%), Torrent Pharma (from 9.28% to 12.87%) and Tech Mahindra (from 32.13% to 36.92%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| TCS | 71.77% | 9.06% | 13.47% | 5.70% | June 2026 |
| Sun Pharma | 52.68% | 14.36% | 22.27% | 10.70% | September 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| Tech Mahindra | 34.97% | 18.66% | 36.92% | 9.45% | June 2026 |
Risks to Weigh in Export Stocks
Being careful with export stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Torrent Pharma trades at a PE of 79.66 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Export Stocks
Picking from export stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (18.27 to 36.42) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track TCS, Sun Pharma, Torrent Pharma and Tech Mahindra live prices.
Conclusion
Among export stocks, TCS stands out for the highest return on equity at 43.37%, Sun Pharma for the fastest profit growth, 35.75% a year since FY22, Torrent Pharma for the biggest five-year price gain at 194.63% and Tech Mahindra for the strongest latest-quarter profit growth at 33.95%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing export stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Export Stocks to Watch
Which are the best export stocks to watch for multibagger potential?
Ans. TCS, Sun Pharma, Torrent Pharma and Tech Mahindra are the 4 names this list highlights, with market caps of Rs 8,40,559 crore, Rs 4,20,024 crore, Rs 1,71,745 crore and Rs 1,59,452 crore respectively. TCS is notable for the highest return on equity at 43.37%. Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22. Torrent Pharma offers the biggest five-year price gain at 194.63%. Tech Mahindra brings the strongest latest-quarter profit growth at 33.95%. These are watchlist names for export stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is TCS a good stock for long-term investors?
Ans. TCS has a return on equity of 43.37%, a PE of 16.21 against an industry PE of 18.27 and a market cap of Rs 8,40,559 crore. Net profit has compounded at 6.49% a year since FY22, and FY26 revenue rose 4.68% while September 2026 quarter net profit grew 14.86%. Long-term returns in export stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Sun Pharma become a multibagger from here?
Ans. Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in export stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.66 against an industry PE of 36.42, valuation should be checked against that growth before investing.
What is the market cap of TCS, Sun Pharma, Torrent Pharma and Tech Mahindra?
Ans. As of 23 October 2026, TCS has a market cap of Rs 8,40,559 crore, Sun Pharma has a market cap of Rs 4,20,024 crore, Torrent Pharma has a market cap of Rs 1,71,745 crore and Tech Mahindra has a market cap of Rs 1,59,452 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on export stocks.
What are the risks of investing in export stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 79.66 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Torrent Pharma trading at a PE of 79.66?
Ans. Torrent Pharma’s PE of 79.66 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in export stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in TCS, Sun Pharma, Torrent Pharma and Tech Mahindra?
Ans. As of the latest reported quarter, FII and DII together hold 22.53% of TCS (9.06% and 13.47%), 36.63% of Sun Pharma (14.36% and 22.27%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 55.58% of Tech Mahindra (18.66% and 36.92%). Rising institutional holding is a useful signal in export stocks, though it should be read with earnings trends rather than on its own.
